PARK2
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
RB7371
unconjugated
Applikationshinweise
Recommended Dilution: WB: 1:1000 Quality Control: Western blots performed on each lot.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
100 μL in 10 mM HEPES ( pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.
Lagerung
-20 °C
Target
Parkin (PARK2)
(Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
Andere Bezeichnung
PARK2
Hintergrund
Parkin is an E3 ligase in the ubiquitin-proteasome system. Hereditary Parkinson’s disease is most commonly caused by mutations in the parkin gene and is characterized by the progressive loss of dopaminergic neurons and the presence of Lewy bodies in the substania nigra (Jenner et al.,1992). Recent evidence suggests that phosphorylation of parkin at Ser378 may have an important regulatory role on its E3 ubiquitin ligase activity (Yamamoto et al., 2005). Anti-Phospho-Ser378 Parkin Western blot of HEK293 cells transfected with Parkin WT (Phospho) and Parkin S378 mutant (non-phospho) showing the phospho-specific immunolabeling of the ~ 52 k parkin protein. The immunolabeling is absent in the parkin S378 mutant.